Share this article
Share this article
ResearchAndMarkets.com s offering.
Antimicrobial Resistance is creating new kinds of infections and superbugs that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market.
We have identified the 6 Key Large Opportunities in this space and developed market forecasts.The publisher has looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play.
This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And the publisher summarizes what technologies they are using.
Depomed Inc (NASDAQ: DEPO) announced Thursday that it will acquire the U.S. rights to the NUCYNTA franchise from Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals, Inc. for $1.05 billion. According to the company’s press release, “The NUCYNTA franchise. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to: